Feasibility of Ambulatory Talc. Pleurodesis
Can Talc Pleurodesis for Malignant Pleural Effusion be Performed on an Ambulatory Basis
David Rollins
15 participants
Jan 10, 2024
INTERVENTIONAL
Conditions
Summary
Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.
Eligibility
Inclusion Criteria3
- Malignant pleural effusion
- Life expectancy >30 days
- WHO PS 1-2 (3 if due to dyspnoea)
Exclusion Criteria2
- Previous failed pleurodesis (on affected side)
- Known non-expansile lung
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06682936